Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 3, 2007, Pages 831-838

  Vidaillac, Céline ^a   Guillon, Jean ^a   Arpin, Corinne ^a   Forfar Bares, Isabelle ^a   Ba, Boubakar B ^a   Grellet, Jean ^a   Moreau, Stéphane ^a   Caignard, Daniel Henri ^b   Jarry, Christian ^a   Quentin, Claudine ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

11 PYRROLO[1,2 A]QUINOXALINE DERIVATIVE; 2[(PYROLLO[1,2 A]QUINOXALINE 4 YL)METHYLSUFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIULCER AGENT; BACTERIAL PROTEIN; BENZIMIDAZOLE; CHLORAMPHENICOL; CHLORINE; CIPROFLOXACIN; EFFLUX PUMP; EFFLUX PUMP INHIBITOR; FUNCTIONAL GROUP; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; OMEPRAZOLE DERIVATIVE; PROTEIN NORA; RESERPINE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; BACTERIAL STRAIN; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARAMETER; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION; TECHNIQUE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CULTURE MEDIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENZYME INHIBITORS; INDICATORS AND REAGENTS; KINETICS; MICROBIAL SENSITIVITY TESTS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NORFLOXACIN; OMEPRAZOLE; STAPHYLOCOCCUS AUREUS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33847652171     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01306-05     Document Type: Article

References (48)

1. Aeschlimann, J. R., L. D. Dresser, G. W. Kaatz, and M. J. Rybak. 1999. Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 43:335-340.
2. Ba, B. B., C. Arpin, C. Vidaillac, A. Chausse, M. C. Saux, and C. Quentin. 2006. Activity of gatifloxacin in an in vitro pharmacokinetic- pharmacodynamic model against Staphylococcus aureus strains susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance. Antimicrob. Agents Chemother. 50:1931-1936.
3. Bischler, A., and B. Napieralski. 1893. Zur Kenntnis einer neuen Isochinolinsynthese. Ber. Dtsch. Chem. 26:1903-1908.
4. Cereda, E., M. Turconi, A. Ezhaya, A. Brambilla, F. Pagani, and A. Donetti. 1987. Anti-secretory and anti-ulcer activities of some new 2-(2-pyridyl-methyl-sulfinyl)-benzimidazoles. Eur. J. Med. Chem. 22:527-535.
5. Ching, M. S., G. W. Mihaly, P. W. Angus, D. J. Morgan, S. Devenish-Meares, and N. D. Yeomans. 1991. Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer. Br. J. Clin. Pharmacol. 31:166-170.
6. +-ATPase inhibitors. Bull. Korean Chem. Soc. 22:1217-1223.
7. Eliopoulos., G. M. 1996. Antimicrobial combinations, p. 330-396. In V. Lorian (ed.), Antibiotics in laboratory medicine. Williams & Wilkins, Baltimore, MD.
8. Elming, N., and N. Clauson-Kaas. 1952. The preparation of pyrroles from furans. Acta Chem. Scand. 6:867-874.
9. Gibbons, S., M. Oluwatuyi, and G. W. Kaatz. 2003. A novel inhibitor of multidrug efflux pumps in Staphylococcus aureus. J. Antimicrob. Chemother. 51:13-17.
10. Guillon, J., B. Pfeiffer, P. Renard, D. Manchez, A. Kervran, and S. Rault. 1998. Synthesis of new pyrrolo[1,2-a]quinoxalines: potential non peptide glucagon receptor antagonist. Eur. J. Med. Chem. 33:293-308.
11. Guillon, J., M. Boulouard, V. Lisowski, S. Stiebing, V. Lelong, P. Dallemagne, and S. Rault. 2000. Synthesis of new 2-(aminomethyl)-4- phenylpyrrolo[1,2-a]-quinoxalines and their preliminary in-vivo central dopamine antagonist activity evaluation in mice. J. Pharm. Pharmacol. 52:1369-1375.
12. Guillon, J., P. Grellier, M. Labaied, P. Sonnet, J. M. Leger, R. Deprez-Poulain, I. Forfar-Bares, P. Dallemagne, N. Lemaitre, F. Pehourcq, J. Rochette, C. Sergheraert, and C. Jarry. 2004. Synthesis, antimalarial activity, and molecular modeling of new pyrrolo[1,2-a]quinoxalines, bispyrrolo[1,2-a]quinoxalines, bispyrido[3,2-e]pyrrolo[1,2- a]pyrazines, and bispyrrolo[1,2-a] thieno[3,2-e]pyrazines. J. Med. Chem. 47:1997-2009.
13. Hellstrom, P. M., and S. Vitols. 2004. The choice of proton pump inhibitor: does it matter? Basic Clin. Pharmacol. Toxicol. 94:106-111.
14. Horn, J. 2000. The proton-pump inhibitors: similarities and differences. Clin. Ther. 22:266-280.
15. +-ATPase inhibitors: the relationship between pyridine basicity, stability and activity. J. Med. Chem. 32:1970-1977.
16. Kaatz, G. W., V. V. Moudgal, S. M. Seo, J. B. Hansen, and J. E. Kristiansen. 2003. Phenylpiperidine selective serotonin reuptake inhibitors interfere with multidrug efflux pump activity in Staphylococcus aureus. Int. J. Antimicrob. Agents 22:254-261.
17. Kaatz, G. W., V. V. Moudgal, S. M. Seo, and J. E. Kristiansen. 2003. Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus. Antimicrob. Agents Chemother. 47:719-726.
18. Kaatz, G. W., S. M. Seo, and T. J. Foster. 1999. Introduction of a norA promoter region mutation into the chromosome of a fluoroquinolone-susceptible strain of Staphylococcus aureus using plasmid integration. Antimicrob. Agents Chemother. 43:2222-2224.
19. Kaatz, G. W., S. M. Seo, and C. A. Ruble. 1993. Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 37:1086-1094.
20. Kaatz, G. W., and S. M. Seo. 1995. Inducible NorA-mediated multidrug resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 39:2650-2655.
21. Kaatz, G. W., and S. M. Seo. 1997. Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 41:2733-2737.
22. Kaatz, G. W. 2005. Bacterial efflux pump inhibition. Curr. Opin. Investig. Drugs 6:191-198.
23. Katsuaki, K., K. Oda, T. Kaneko, H. Satoh, and A. Nohara. 1990. Synthesis of 2-[[(4-fluoroalkoxy-2-pyridyl)methyl]sulfinyl]-1H- benzimidazoles as anti-ulcer agents. Chem. Pharm. Bull. 38:2853-2858.
24. Klyachko, K. A., S. Schuldiner, and A. A. Neyfakh. 1997. Mutations affecting substrate specificity of the Bacillus subtilis multidrug transporter Bmr. J. Bacteriol. 179:2189-2193.
25. Lewis, K. 2001. In search of natural substrates and inhibitors of MDR pumps. J. Mol. Microbiol. Biotechnol. 3:247-254.
26. Li, X. Z., and H. Nikaido. 2004. Efflux-mediated drug resistance in bacteria. Drugs 64:159-204.
27. Lomovskaya, O., and W. J. Watkins. 2001. Efflux pumps: their role in antibacterial drug discovery. Curr. Med. Chem. 8:1699-1711.
28. Markham, P. N., E. Westhaus, K. Klyachko, M. E. Johnson, and A. A. Neyfakh. 199.9. Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus. Antimicrob. Agents Chemother. 43:2404-2408.
29. Marquez, B. 2005. Bacterial efflux systems and efflux pumps inhibitors. Biochimie 87:117-147.
30. McKeegan, K. S., M. I. Borges-Walmsley, and A. R. Walmsley. 2004. Structural understanding of efflux-mediated drug resistance: potential routes to efflux inhibition. Curr. Opin. Pharmacol. 4:479-486.
31. Members of the SFM Antibiogram Committee. 2003. Comité de l'Antibiogramme de la Société Française de Microbiologie Report 2003. Int. J. Antimicrob. Agents 21:364-391.
32. Mullin, S., N. Mani, and T. H. Grossman. 2004. Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853). Antimicrob. Agents Chemother. 48:4171-4176.
33. Paulsen, I. T., M. H. Brown, and R. A. Skurray. 1996. Proton-dependent multidrug efflux systems. Microbiol. Rev. 60:575-608.
34. Pereda-Miranda, R., G. W. Kaatz, and S. Gibbons. 2006. Polyacylated oligosaccharides from medicinal Mexican morning glory species as antibacterials and inhibitors of multidrug resistance in Staphylococcus aureus. J. Nat. Prod. 69:406-409.
35. Piddock, L. J., M. M. Johnson, S. Simjee, and L. Pumbwe. 2002. Expression of efflux pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46:808-812.
36. Putman, M., H. W. van Veen, and W. N. Konings. 2000. Molecular properties of bacterial multidrug transporters. Microbiol. Mol. Biol. Rev. 64:672-693.
37. 3 for conversion of nitroarenes to primary amines. Synth. Commun. 25:3799-3803.
38. Rottenberg, H. 1979. The measurement of membrane potential and deltapH in cells, organelles, and vesicles. Methods Enzymol. 55:547-569.
39. Ryan, B. M., T. J. Dougherty, D. Beaulieu, J. Chuang, B. A. Dougherty, and J. F. Barrett. 2001. Efflux in bacteria: what do we really know about it? Expert Opin. Investig. Drugs 10:1409-1422.
40. Sachs, G., and J. M. Shin. 2004. The basis of differentiation of PPIs. Drugs Today (Barcelona) 40:9-14.
41. Samosorn, S., J. B. Bremner, A. Ball, and K. Lewis. 2006. Synthesis of functionalized 2-aryl-5-nitro-1H-indoles and their activity as bacterial NorA efflux pump inhibitors. Bioorg. Med. Chem. 14:857-865.
42. Takenouchi, T., F. Tabata, Y. Iwata, H. Hanzawa, M. Sugawara, and S. Ohya. 1996. Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1835-1842.
43. Van Bambeke, F., Y. Glupczynski, P. Plesiat, J. C. Pechere, and P. M. Tulkens. 2003. Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J. Antimicrob. Chemother. 51:1055-1065.
44. Wei, P., G. W. Kaatz, and R. J. Kerns. 2004. Structural differences between paroxetine and femoxetine responsible for differential inhibition of Staphylococcus aureus efflux pumps. Bioorg. Med. Chem. Lett. 14:3093-3097.
45. Whaley, W. M., and T. R. Govindachari. 1951. Synthesis of isoquinolines. Org. React. 6:74-150.
46. Yoshida, S., T. Kojima, M. Inoue, and S. Mitsuhashi. 1991. Uptake of sparfloxacin and norfloxacin by clinical isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 35:368-370.
47. Yu, J. L., L. Grinius, and D. C. Hooper. 2002. NorA functions as a multidrug efflux protein in both cytoplasmic membrane vesicles and reconstituted proteoliposomes. J. Bacteriol. 184:1370-1377.
48. Yuen, K. H., W. P. Choy, H. Y. Tan, J. W. Wong, and S. P. Yap. 2001. Improved high performance liquid chromatographic analysis of omeprazole in human plasma. J. Pharm. Biomed. Anal. 24:715-719.